Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1) - Join Clinical Trial NCTNCT04980833
How to Join This Clinical Trial - NCTNCT04980833
Learn how to participate in this PHASE2 trial studying an investigational therapy for PIK3CA-related Overgrowth Spectrum (PROS). Current status: ACTIVE_NOT_RECRUITING.
Am I Eligible for This Clinical Trial?
This clinical research study is looking for participants with PIK3CA-related Overgrowth Spectrum (PROS). Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.
- Condition Being Studied
- PIK3CA-related Overgrowth Spectrum (PROS)
- Treatment Being Tested
- Investigational treatment
- Study Phase
- PHASE2 - Safety and effectiveness study
- Enrollment Status
- ACTIVE_NOT_RECRUITING
- Study Identifier
- NCTNCT04980833 - ClinicalTrials.gov Identifier
- Sponsored By
- Study sponsor
What to Expect as a Participant
Participating in this clinical trial involves:
- Initial screening to determine eligibility
- Regular study visits and health assessments
- Receiving the study treatment or placebo
- Medical monitoring and follow-up care
- Contributing to medical research that may help others
- Potential access to new treatments before they're widely available
Clinical Trial Benefits and Compensation
Participants in this clinical research study may receive:
- Close medical monitoring by healthcare professionals
- Access to potential new treatments
- Compensation for time and travel (varies by study)
- No-cost study-related medical care
- The opportunity to help advance medical knowledge
Where Is This Clinical Trial Located?
This study is enrolling participants at 6 locations. Find a study site near you:
Clinical Research Site
Boston, Massachusetts 02215 - United States
Status: Contact for availability
Clinical Research Site
Dijon, 21034 - France
Status: Contact for availability
Clinical Research Site
Montpellier, 34295 - France
Status: Contact for availability
Clinical Research Site
Paris, 75015 - France
Status: Contact for availability
Clinical Research Site
Dublin, 12 - Ireland
Status: Contact for availability
Clinical Research Site
Madrid, 28046 - Spain
Status: Contact for availability
How to Enroll in This Study
To learn more about participating in this PHASE2 clinical trial for PIK3CA-related Overgrowth Spectrum (PROS):
- Review the eligibility criteria with your healthcare provider
- Contact the study team for a pre-screening interview
- Schedule an in-person screening visit if eligible
- Review and sign the informed consent form
- Begin participation in the clinical trial
Why Choose Quri.ai Study Finder
Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:
- Discover clinical trials before competitors
- Access exclusive contact information
- Track sponsor pipelines and opportunities
- Connect with decision makers directly
- Win more business partnerships